GELS vs KZIA
Gelteq Ltd. and Kazia Therapeutics Ltd., side by side — 2 fiscal years reported in AUD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | GELS | KZIA |
|---|---|---|
| Revenue | AUD 165,645 | AUD 42,000 |
| Net income | $-6.6M | AUD -20.7M |
| Gross margin | 30.3% | · |
| Net margin | · | · |
| Return on equity | −43.0% | · |
| Diluted EPS | −AUD 0.72 | −AUD 0.04 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | AUD -5.5M | · |
| Equity | · | AUD -8.3M |
| Net debt / equity | 0.25× | · |
| Current ratio | 0.27× | 0.35× |
| Revenue CAGR 5y | · | · |
| Profit CAGR 5y | · | · |
GELS bills 3.9× the revenue of KZIA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
Revenue by year
2 years side by side
| Fiscal year | GELS | KZIA |
|---|---|---|
| FY2024 | AUD 165,645 | AUD 42,000 |
| FY2022 | AUD 79,843 | AUD 0 |
Net income by year
Bottom line
| Fiscal year | GELS | KZIA |
|---|---|---|
| FY2024 | $-6.6M | AUD -20.7M |
| FY2022 | · | AUD -20.5M |